VERTEX PHARMACEUTICALS INC / MA (VRTX) Free cash flow 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$3.2BFY2025 · since FY2016: $179.5M → $3.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.2B | +504.1% |
| FY2024 | -$790.3M | -123.7% |
| FY2023 | $3.3B | -15.0% |
| FY2022 | $3.9B | +63.0% |
| FY2021 | $2.4B | -19.5% |
| FY2020 | $3.0B | +100.4% |
| FY2019 | $1.5B | +27.2% |
| FY2018 | $1.2B | +57.6% |
| FY2017 | $745.5M | +315.2% |
| FY2016 | $179.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice